论文部分内容阅读
对比研究并分析经导管肝动脉化疗栓塞手术(TACE)与静脉化疗治疗老年食道癌肝转移瘤患者的临床治疗效果。对54例食道癌肝转移瘤老年患者的临床治疗资料及随访等资料做回顾性分析,本次研究的54例患者主要是采用经导管肝动脉化疗栓塞手术(TACE)与静脉化疗治疗,其中采用TACE治疗的患者有23例(命名为TACE组),采用静脉化疗的患者有31例(命名为静脉化疗组),两组患者都采用FOLFOX4方案进行化疗,经一段时间的治疗后比较两组患者的临床疗效以及远期预后。TACE组患者经治疗后缓解率为60.87%,静脉化疗组经治疗后缓解率为19.35%,两组患者之间的缓解率存在明显的差异性,有统计学意义(P<0.05);TACE组患者经治疗后其总有效率为86.96%(20/23)明显高于静脉化疗组患者的总有效率77.42%(24/31),两组患者治疗总有效率之间的差异没有统计学意义(P>0.05)。两组患者经治疗后进行KPS评分,其中TACE组的评分(85.3±4.1)分比静脉化疗组(80.8±3.9)分要高,两组之间的KPS评分存在统计学意义(P<0.05)。随访两组患者治疗后1、2、3年后的生存率,两组患者之间的生存时间的差异有统计学意义(P<0.05)。采用TACE治疗老年食道癌肝转移瘤患者相对于静脉化疗治疗取得的近期疗效更好,能明显改善患者的生存质量,从远期疗效方面相比其优势不明显。
A comparative study and analysis of the clinical efficacy of transcatheter arterial chemoembolization (TACE) and intravenous chemotherapy in elderly patients with esophageal cancer liver metastases. Clinical data and follow-up data of 54 esophageal cancer patients with liver metastases were retrospectively analyzed. The 54 patients in this study were mainly treated with transcatheter arterial chemoembolization (TACE) and intravenous chemotherapy. There were 23 patients (named TACE group) treated with TACE and 31 patients (named intravenous chemotherapy group) treated with intravenous chemotherapy. Both groups were treated with FOLFOX4 chemotherapy. After a period of treatment, the two groups of patients were compared. The clinical efficacy and long-term prognosis. The remission rate was 60.87% in the TACE group and 19.35% in the intravenous chemotherapy group. There was a significant difference in the remission rate between the two groups (P<0.05); TACE group After treatment, the total effective rate was 86.96% (20/23), which was significantly higher than the total effective rate of 77.42% (24/31) in the intravenous chemotherapy group. There was no significant difference between the two groups in the total treatment efficiency. (P>0.05). KPS scores were obtained after treatment in both groups. The scores in the TACE group (85.3±4.1) were higher than those in the intravenous chemotherapy group (80.8±3.9). The KPS scores between the two groups were statistically significant (P<0.05). . The survival rate of the two groups was followed up after 1, 2 and 3 years. There was a significant difference in the survival time between the two groups (P<0.05). The use of TACE in the treatment of esophageal cancer patients with liver metastases has a better short-term outcome than intravenous chemotherapy. It can significantly improve the patient’s quality of life, and its advantage over the long-term efficacy is not obvious.